-

Rion to Present at the 42nd Annual J.P. Morgan Healthcare Conference

ROCHESTER, Minn.--(BUSINESS WIRE)--Rion, a leader in regenerative medicine and exosome technology, today announced Dr. Atta Behfar, Co-Founder, will present at the 42nd Annual JP Morgan Healthcare Conference on Wednesday, January 10, 2024, at 02:00 PM. The presentation will showcase Rion's breakthrough developments in platelet-derived regenerative exosome technology and its significant impact across various regenerative medicine therapeutic areas.

“I am honored to be presenting at the JP Morgan Healthcare Conference, and to have the opportunity to share with other industry leaders our breakthrough regenerative exosome technology as we build a new therapeutic platform," said Dr. Atta Behfar, Co-Founder of Rion. "This platform allows us to highlight Rion's significant contributions to regenerative medicine and discuss our innovative regenerative exosome technology with a global audience.”

About Rion

Rion is a clinical-stage regenerative medicine company focused on developing innovative exosome therapeutics based on platelet-derived regenerative exosomes. Rion has built a proprietary exosome engineering and manufacturing platform for Platelet Exosome Product (PEPTM), an innovative and commercially viable biologic platform that optimizes the therapeutic power of exosomes for regenerative medicine. RION was established in 2017 and is headquartered in Rochester, Minnesota.

Contacts

Scott McCrea at mccrea@riontx.com

Industry:

Rion

Release Versions
English

Contacts

Scott McCrea at mccrea@riontx.com

More News From Rion

INTENT Biologics Receives FDA Agreement Granting a Full Waiver for its Pediatric Study Plan for PEP Biologic™ in Advanced Wound Care

ROCHESTER, Minn.--(BUSINESS WIRE)--INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has agreed to INTENT’s Initial Pediatric Study Plan (iPSP) for PEP Biologic™ under IND 019567, supporting the company’s request for a full pediatric waiver for its forthcoming Biologics License Applicati...

INTENT Biologics Receives FDA Fast Track Designation for PEP Biologic™

ROCHESTER, Minn.--(BUSINESS WIRE)--INTENT Biologics, a clinical-stage biotechnology company developing first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for PEP Biologic™ for the treatment of diabetic foot ulcers (DFU) under IND 019567. FDA Fast Track designation is designed to facilitate the development and expedite the review of drugs an...

CORRECTING and REPLACING RION Launches RION Vet to Transform Animal Health with First-in-Class Biologic Therapeutic; Appoints Industry Leader Mark Herthel as CEO; Announces Series A Fulfillment

ROCHESTER, Minn.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The updated release reads: RION LAUNCHES RION VET TO TRANSFORM ANIMAL HEALTH WITH FIRST-IN-CLASS BIOLOGIC THERAPEUTIC; APPOINTS INDUSTRY LEADER MARK HERTHEL AS CEO; ANNOUNCES SERIES A FULFILLMENT RION, a clinical-stage regenerative medicine company and global leader in exosome-based therapeutics, today announced the formation of RION Vet, a veterinary biotechnology compa...
Back to Newsroom